Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients (MBC)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified December 2013 by Immunovative Therapies, Ltd.
Sponsor:
Information provided by (Responsible Party):
Immunovative Therapies, Ltd.
ClinicalTrials.gov Identifier:
NCT02018419
First received: December 17, 2013
Last updated: NA
Last verified: December 2013
History: No changes posted
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is not yet open for participant recruitment.
  Estimated Study Completion Date: March 2017
  Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Publications: